Literature DB >> 10636873

alpha(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels.

I M Keularts1, R M van Gorp, M A Feijge, W M Vuist, J W Heemskerk.   

Abstract

alpha(2A)-Adrenergic receptor-mediated Ca(2+) signaling and integrin alpha(IIb)beta(3) exposure were investigated in human platelets under conditions where indirect, thromboxane- or ADP-mediated effects were absent. The alpha(2)-adrenergic receptor agonists, UK14304 and epinephrine (EPI), were unable to raise cytosolic levels of inositol 1,4,5-trisphosphate (InsP(3)) or Ca(2+) but potentiated the [Ca(2+)](i) rises evoked by other agonists that act through stimulation of phospholipase C (thrombin or platelet-activating factor) or stimulation of Ca(2+)-induced Ca(2+) release (CICR) in the absence of InsP(3) generation (thimerosal or thapsigargin). In addition, alpha(2)-adrenergic stimulation resulted in a 20% lowering in the cytosolic cAMP level. In platelets treated with G(salpha)-stimulating prostaglandin E(1), EPI increased the Ca(2+) signal evoked by either phospholipase C- or CICR-stimulating agonists mainly through modulation of the cAMP level. The stimulating effects of UK14304 and EPI on platelet Ca(2+) responses, and also on integrin alpha(IIb)beta(3) exposure and platelet aggregation, were abolished by pharmacological stimulation of cAMP-dependent protein kinase, and these effects were mimicked by inhibition of this activity. In permeabilized platelets, UK14304 and EPI potentiated InsP(3)-induced, CICR-mediated mobilization of Ca(2+) from internal stores in a similar way as did inhibition of cAMP-dependent protein kinase. In summary, a G(ialpha)-mediated decrease in cAMP level appears to play a major role in the platelet-activating effects of alpha(2A)-adrenergic receptor stimulation. Thus, in platelets, unlike other cell types, occupation of the G(ialpha)-coupled alpha(2A)-adrenergic receptors does not result in phospholipase C activation but rather in modulation of the Ca(2+) response by relieving cAMP-mediated suppression of InsP(3)-dependent CICR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10636873     DOI: 10.1074/jbc.275.3.1763

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  ADP and platelets: the end of the beginning.

Authors:  D Woulfe; J Yang; L Brass
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs.

Authors:  J Yang; J Wu; M A Kowalska; A Dalvi; N Prevost; P J O'Brien; D Manning; M Poncz; I Lucki; J A Blendy; L F Brass
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).

Authors:  Michele M Mumaw; Maria de la Fuente; Amal Arachiche; James K Wahl; Marvin T Nieman
Journal:  Thromb Res       Date:  2015-04-09       Impact factor: 3.944

Review 4.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

Review 5.  Platelet signaling.

Authors:  Timothy J Stalker; Debra K Newman; Peisong Ma; Kenneth M Wannemacher; Lawrence F Brass
Journal:  Handb Exp Pharmacol       Date:  2012

6.  P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries.

Authors:  Patrick Andre; Suzanne M Delaney; Thomas LaRocca; Diana Vincent; Francis DeGuzman; Marzena Jurek; Beverley Koller; David R Phillips; Pamela B Conley
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

7.  Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.

Authors:  Jesica R Williams; Anna L Khandoga; Pankaj Goyal; James I Fells; Donna H Perygin; Wolfgang Siess; Abby L Parrill; Gabor Tigyi; Yuko Fujiwara
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

8.  Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

Authors:  M Campos-Toimil; T Keravis; F Orallo; K Takeda; C Lugnier
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

9.  Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.

Authors:  M M Mumaw; M de la Fuente; D N Noble; M T Nieman
Journal:  J Thromb Haemost       Date:  2014-06-27       Impact factor: 5.824

10.  Heat shock protein 70 regulates platelet integrin activation, granule secretion and aggregation.

Authors:  Rachel A Rigg; Laura D Healy; Marie S Nowak; Jérémy Mallet; Marisa L D Thierheimer; Jiaqing Pang; Owen J T McCarty; Joseph E Aslan
Journal:  Am J Physiol Cell Physiol       Date:  2016-01-13       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.